
mAbxience CDMO
24.000 l Einwegkapazität für die GMP-Herstellung antikörperähnlicher Moleküle
Batch Size: Large, Medium
Compliance: ISO, TITCK (Turkish Health Authorities), ANVISA (Brazil B-GMP), COFEPRIS, ICH, MHRA (UK GMP), ANMAT (Argentina nueva GMP), ISP (Chile BPM), World Health Organization (GMP / HACCP), EMA (EU GMP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), ANVISA (Brazil), MHRA (UK)
Markets: ANMAT (Argentina), Rest der Welt, COFEPRIS (Mexico), Russian Health Authorities, EDE (UAE), ANVISA (Brazil), ISP (Chile), DIGEMID (Peru), Turkish Health Authorities, EMA (EU), INVIMA (Colombia), SFDA (Saudi Arabia)
Use: Human
Services: Analytical / QC services, Manufacturing services
Therapeutic Areas of Expertise (ATC): (B) Blood and blood forming organs, (D) Dermatologicals, (N) Nervous system, (J) Antiinfectives for systemic use, (R) Respiratory system, (P) Antiparasitic products, insecticides and repellents, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
Region: Europe
Category / Product: BIOLOGICS

mAbxience CDMO
24.000 l Einwegkapazität für die Entwicklung antikörperähnlicher Moleküle und die GMP-Herstellung, von der Zelllinienentwicklung bis zur kommerziellen Arzneimittelsubstanz
Batch Size: Large, Small, Medium
Compliance: ISO, TITCK (Turkish Health Authorities), ANVISA (Brazil B-GMP), COFEPRIS, ICH, FDA (cGMP), PMDA/MHLW (Japan GMP), Health Canada (Canada GMP), MHRA (UK GMP), ANMAT (Argentina nueva GMP), TGA (Australia GMP), Roszdravnadzor (Russia GMP), ECOVADIS, ISP (Chile BPM), French Service-Public (CIR), World Health Organization (GMP / HACCP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), PMDA (Japan), ANVISA (Brazil), Health Canada, MHRA (UK), TGA (Australia)
Markets: FDA (USA), PMDA (Japan), Health Canada (Canada), ANMAT (Argentina), Rest der Welt, COFEPRIS (Mexico), Russian Health Authorities, EDE (UAE), ANVISA (Brazil), ISP (Chile), DIGEMID (Peru), Turkish Health Authorities, EMA (EU), MHRA (UK), MFDS (South Korea), INVIMA (Colombia), MSPAS (Guatemala), SFDA (Saudi Arabia), TGA (Australia)
Use: Human, Veterinary
Services: Development services, Analytical / QC services, Manufacturing services, Quality Assurance services
Therapeutic Areas of Expertise (ATC): (B) Blood and blood forming organs, (D) Dermatologicals, (N) Nervous system, (J) Antiinfectives for systemic use, (R) Respiratory system, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (H) Systemic hormonal preparations excl. sex hormones and insulins, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
Region: Europe
Category / Product: BIOLOGICS
Compliance: ANMAT (Argentina nueva GMP)
Markets: ANMAT (Argentina), Rest der Welt
Services: Development services, Manufacturing services
Region: Europe
Category / Product: BIOLOGICS

Bilthoven Biologicals BV
GMP-Anlagen für mehrere Produkte für Arzneimittelsubstanzen und Arzneimittelprodukte.
Markets: EMA (EU), MHRA (UK)
Batch Size: Large, Small, Medium
BSL (Biological Safety Level): 1, 2
Services: Development services, Logistics, Analytical / QC services, Manufacturing services, Quality Assurance services, Regulatory services, Packaging
Use: Human
Compliance: EMA (EU GMP)
Category / Product: FDF / DRUG PRODUCTS, ANALYTISCHE CRO, BIOLOGICS
Region: Europe

CZ Vaccines
Einrichtung für klinische Studien
Services: Development services, Logistics, Analytical / QC services, Manufacturing services, Quality Assurance services, Regulatory services, Packaging
Markets: EMA (EU), ANVISA (Brazil), CDSCO (India)
Use: Human
BSL (Biological Safety Level): 1, 2
Compliance: ISO, ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), EMA (EU GMP)
Batch Size: Small
Category / Product: FDF / DRUG PRODUCTS, BIOLOGICS
Therapeutic Areas of Expertise (ATC): (R) Respiratory system, (G) Genito urinary system and sex hormones, (A) Digestive tract and metabolism
Region: Europe

CARBOGEN AMCIS
Entwicklung und cGMP-Herstellung im mittleren Maßstab einschließlich Chromatographie.
Use: Human, Veterinary
Markets: FDA (USA), EMA (EU), PMDA (Japan), NMPA (China), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), CDSCO (India), MFDS (South Korea), TGA (Australia)
Services: Development services, Analytical / QC services, Manufacturing services, Quality Assurance services
Compliance: ISO, FDA (cGMP), PMDA/MHLW (Japan GMP), World Health Organization (GMP / HACCP)
Batch Size: Small, Medium
Category / Product: ANALYTISCHE CRO, PARTICLE ENGINEERING, BIOLOGICS, CHEMICAL-SYNTHETIC
OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 5,000 µg/day), 2 (PDE = 1,000 - 5,000 µg/day)
Region: Europe

CARBOGEN AMCIS
Entwicklung und cGMP-Herstellung hochwirksamer Wirkstoffe, einschließlich Antikörper-Wirkstoff-Konjugaten (ADC).
Services: Development services, Analytical / QC services, Regulatory services, Quality Assurance services, Manufacturing services
Markets: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), Turkish Health Authorities, CDSCO (India), TGA (Australia)
Compliance: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)
Use: Human, Veterinary
Therapeutic Areas of Expertise (ATC): (V09-10) Radiopharmaceuticals, (N) Nervous system, (D) Dermatologicals, (B) Blood and blood forming organs, (R) Respiratory system, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (C) Cardiovascular system, (A) Digestive tract and metabolism
Batch Size: Small, Medium
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 5,000 µg/day)
Category / Product: PARTICLE ENGINEERING, ANALYTISCHE CRO, BIOLOGICS, CHEMICAL-SYNTHETIC
Region: Europe

HIPRA Biotech Services
Interne End-to-End-Fähigkeiten von der Zelllinienentwicklung bis zur kommerziellen Fertigung.
Services: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services
Markets: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia)
Compliance: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)
BSL (Biological Safety Level): 1, 2
Use: Human
Batch Size: Large, Small, Medium
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 2 (PDE = 1,000 - 5,000 µg/day)
Region: Europe
Category / Product: BIOLOGICS

Services: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services
Markets: EMA (EU)
Compliance: ISO, EMA (EU GMP), World Health Organization (GMP / HACCP)
BSL (Biological Safety Level): 1, 2
Use: Human
Batch Size: Large, Medium
Therapeutic Areas of Expertise (ATC): (J) Antiinfectives for systemic use, (R) Respiratory system, (G) Genito urinary system and sex hormones
Category / Product: FDF / DRUG PRODUCTS, BIOLOGICS
Region: Europe

Green Phoenix Labs GmbH
Lizenzierter ATMP-Standort in Deutschland. GMP-Herstellung und QP-Chargenfreigabe für Zell- und Gewebetherapien.
Services: Development services, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services
Markets: EMA (EU)
BSL (Biological Safety Level): 1, 2
Use: Human
Controlled Substances: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse
Therapeutic Areas of Expertise (ATC): (S) Sensory organs, (N) Nervous system, (D) Dermatologicals, (B) Blood and blood forming organs, (R) Respiratory system, (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
Batch Size: Small, Medium
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 2 (PDE = 1,000 - 5,000 µg/day)
Compliance: EMA (EU GMP)
Category / Product: FDF / DRUG PRODUCTS, ANALYTISCHE CRO, BIOLOGICS
Region: Europe

HIPRA Biotech Services
Interne End-to-End-Fähigkeiten von der Zelllinienentwicklung bis zur kommerziellen Fertigung.
Services: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services
Markets: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia)
Compliance: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)
BSL (Biological Safety Level): 1, 2
Use: Human, Veterinary
Batch Size: Large, Small, Medium
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 2 (PDE = 1,000 - 5,000 µg/day)
Category / Product: FDF / DRUG PRODUCTS, BIOLOGICS
Region: Europe

VIVEbiotech
Ihr führender GMP-zertifizierter CDMO, der sich ausschließlich der Produktion lentiviraler Vektoren widmet.
Markets: EMA (EU), FDA (USA), MHRA (UK)
Region: Europe
Compliance: FDA (cGMP), French Service-Public (CIR), EMA (EU GMP), MHRA (UK GMP)
Batch Size: Large, Small, Medium
Use: Human
BSL (Biological Safety Level): 1, 2
Services: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
Category / Product: BIOLOGICS
Register to unlock the full catalog with contact details and locations.
+35 more facilities
Create free accountSind Sie ein pharmazeutisches Unternehmen und suchen einen zuverlässigen CMO- oder CDMO-Partner, um Ihren Arzneimittelentwicklungsprozess zu beschleunigen? Suchen Sie nicht weiter als MAI CDMO Network. Unsere fortschrittliche Suchplattform verbindet Sie mit einem umfangreichen Netzwerk von qualifizierten Auftragsherstellern und Entwicklungsorganisationen weltweit.
Warum MAI CDMO Network wählen?
So funktioniert MAI CDMO Network
Die wichtigsten Vorteile einer Partnerschaft mit einer CMO/CDMO
Ausgewählte Dienstleistungen
Sind Sie bereit, Ihren idealen CMO/CDMO-Partner zu finden? Jetzt registrieren
Erkunden Sie noch heute unsere Plattform und entdecken Sie, wie MAI CDMO Network Ihnen helfen kann, Ihre Ziele in der Arzneimittelentwicklung zu erreichen.